본문 바로가기
KERD
논문KCI 등재

Effect of the Single Oral Combination Treatment of Tamoxifen with Gamisoyo-san on the Pharmacokinetics Profiles of Tamoxifen

구세광|이영준|김주익
한의병리학회 (The Society of Pathology in Korean Medicine)|2020.08|동의생리병리학회지 (Journal of Physiology & Pathology in Korean Medicine)|제34권 제4호|pp. 201-208|DOI 10

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

PharmacokineticsDrug-drug interactionsRatTamoxifenGamisoyo-san
주제분류한의학

초록

The effects of Gamisoyo-san (GMSYS) co-administration within 5 min on the pharmacokinetics (PK) of tamoxifen were observed. After 50 mg/kg of tamoxifen oral treatment, GMSYS 100 mg/kg was orally administered within 5 min to 7-wk old male SPF.VAF Outbred Crl:CD [Sprague-Dawley (SD)] rats. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of GMSYS treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. Tmax, Cmax, AUC, t1/2 and MRTinf of tamoxifen were analysis as compared with tamoxifen single administered rats. Although co-administration with GMSYS did not critically influenced on the pharmacokinetic parameters of oral tamoxifen, they induced increased trends of plasma tamoxifen concentrations, especially significant (p<0.05) increases of plasma tamoxifen concentrations were demonstrated at 0.5 hr after end of co-administration with GMSYS as compared with tamoxifen single formula treated rats, at dosage levels of tamoxifen 10 mg/kg and GMSYS 100 mg/kg within 5 min. It is considered that pharmacokinetic studies should be tested like the effects of GMSYS on the pharmacokinetics of tamoxifen, when they were co-administered with prolonger intervals than Tmax of tamoxifen oral administration (about 2.5 hr-intervals), to achieve the optimal dosing regimen of GMSYS and tamoxifen co-administration.

Abstract

The effects of Gamisoyo-san (GMSYS) co-administration within 5 min on the pharmacokinetics (PK) of tamoxifen were observed. After 50 mg/kg of tamoxifen oral treatment, GMSYS 100 mg/kg was orally administered within 5 min to 7-wk old male SPF.VAF Outbred Crl:CD [Sprague-Dawley (SD)] rats. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of GMSYS treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. Tmax, Cmax, AUC, t1/2 and MRTinf of tamoxifen were analysis as compared with tamoxifen single administered rats. Although co-administration with GMSYS did not critically influenced on the pharmacokinetic parameters of oral tamoxifen, they induced increased trends of plasma tamoxifen concentrations, especially significant (p<0.05) increases of plasma tamoxifen concentrations were demonstrated at 0.5 hr after end of co-administration with GMSYS as compared with tamoxifen single formula treated rats, at dosage levels of tamoxifen 10 mg/kg and GMSYS 100 mg/kg within 5 min. It is considered that pharmacokinetic studies should be tested like the effects of GMSYS on the pharmacokinetics of tamoxifen, when they were co-administered with prolonger intervals than Tmax of tamoxifen oral administration (about 2.5 hr-intervals), to achieve the optimal dosing regimen of GMSYS and tamoxifen co-administration.

참고문헌 (42)

  1. The BIG 1-98 Collaborative Group, "Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer", N Engl J Med, 361(8), pp.766~776 (2009)
  2. Jordan VC, "Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer", Br J Pharmacol, 147(Suppl 1), pp.S269~S276 (2006)
  3. van Bommel EF, "Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis", Ann Intern Med, 144(2), pp.101~106 (2006)
  4. Fradet Y, "Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study", Eur Urol, 52(1), pp.106~114 (2007)
  5. Hurtado A, "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen", Nature, 456(7222), pp.663~666 (2008)
  6. Vehmanen L, "Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status", J Clin Oncol, 24(4), pp.675~680 (2006)
  7. Grilli S, "Tamoxifen (TAM): the dispute goes on", Ann Ist Super Sanita, 42(2), pp.170~173 (2006)
  8. Decensi A, "Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial", Circulation, 111(5), pp.650~656 (2005)
  9. Osman KA, "Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?", Expert Opin Drug Saf, 6(1), pp.1~4 (2007)
  10. Paganini-Hill A, "Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen", Breast Cancer Res Treat, 64(2), pp.165~176 (2000)
  11. Eberling JL, "Estrogen-and tamoxifen-associated effects on brain structure and function", Neuroimage, 21(1), pp.364~371 (2004)
  12. Cella D, "Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer", Breast Cancer Res Treat, 100(3), pp.273~284 (2006)
  13. Karimian E, "Tamoxifen impairs both longitudinal and cortical bone growth in young male rats", J Bone Miner Res, 23(8), pp.1267~1277 (2008)
  14. Nalbandian G, "The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation", J Immunol, 175(4), pp.2666~2675 (2005)
  15. Rousset-Jablonski C, "Tamoxifen contraindicated in women with hereditary angioedema?", Ann Oncol, 20(7), pp.1281~1282 (2009)
  16. Fisher B, "Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study", J Natl Cancer Inst, 90(18), pp.1371~1388 (1998)
  17. Pienta KJ, "A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate", Am J Clin Oncol, 19(5), pp.500~503 (1996)
  18. Braems G, "Use of tamoxifen before and during pregnancy", Oncologist, 16(11), pp.1547~1551 (2011)
  19. Terauchi M, "Effects of three Kampo formulae: Tokishakuyakusan (TJ-23), Kamishoyosan (TJ-24), and Keishibukuryogan (TJ-25) on Japanese peri- and postmenopausal women with sleep disturbances", Arch Gynecol Obstet, 284(4), pp.913~921 (2011)
  20. Hidaka T, "Kami-shoyo-san, Kampo (Japanese traditional medicine), is effective for climacteric syndrome, especially in hormone-replacement-therapy-resistant patients who strongly complain of psychological symptoms", J Obstet Gynaecol Res, 39(1), pp.223~228 (2013)
  21. Kimura Y, "Kampo therapy for premenstrual syndrome: efficacy of Kamishoyosan quantified using the second derivative of the fingertip photoplethysmogram", J Obstet Gynaecol Res, 33(3), pp.325~332 (2007)
  22. Qu Y, "Study on the effect of Jia-Wei-Xiao-Yao-San decoction on patients with functional dyspepsia", Phytother Res, 24(2), pp.245~248 (2010)
  23. Ishikawa T, "Effectiveness of the Kampo kami-shoyo-san(TJ-24)for tremor of antipsychotic-induced parkinsonism", Psychiatry Clin Neurosci, 54(5), pp.579~582 (2000)
  24. Jung MY, "Analysis and Identification of Active Compounds from Gami-Soyosan Toxic to MCF-7 Human Breast Adenocarcinoma Cells", Biomolecules, 9(7) (2019)
  25. Bailer AJ, "Testing for the equality of area under the curves when using destructive measurement techniques", J Pharmacokinet Biopharm, 16(3), pp.303~309 (1988)
  26. Chiou WL, "Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve", J Pharmacokinet Biopharm, 6(6), pp.539~546 (1978)
  27. Adam HK, "Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers", Cancer Treat Rep, 64(6-7), pp.761~764 (1980)
  28. Murphy C, "Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry(GC-MS)using selected ion monitoring(SIM)", J Steroid Biochem, 26(5), pp.547~555 (1987)
  29. Jordan VC, "identification, pharmacology, and significance", Breast Cancer Res Treat, 2(2), pp.123~138 (1982)
  30. Sun D, "Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases", Drug Metab Dispos, 35(11), pp.2006~2014 (2007)
  31. Hall WA, "Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas", J Neurooncol, 77(3), pp.279~284 (2006)
  32. Notley LM, "Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its a-hydroxy and a,4-dihydroxy derivatives", Chem Res Toxicol, 18(10), pp.1611~1618 (2005)
  33. Lien EA, "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide", Cancer Res, 50(18), pp.5851~5857 (1990)
  34. Tenni P, "Life threatening interaction between tamoxifen and warfarin", BMJ, 298(6666), pp.93~ (1989)
  35. Lamberts SW, "Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells", J Clin Endocrinol Metab, 63(6), pp.1342~1347 (1986)
  36. Dowsett M, "Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer", Clin Cancer Res, 5(9), pp.2338~2343 (1999)
  37. Reid AD, "Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients", Breast Cancer Res Treat, 22(2), pp.153~156 (1992)
  38. Dehal SS, "The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy", Drug Metab Dispos, 27(3), pp.389~394 (1999)
  39. West CM, "Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells", Cancer Lett, 55(2), pp.159~163 (1990)
  40. Williams JA, "Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7", Drug Metab Dispos, 30(8), pp.883~891 (2002)
  41. 곽민아, "Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (1) - Single Oral Combination Treatment of Tamoxifen 50mg", kg with JEKHT 100 mg, 대한한의학회지, pp.2016, 37(2)[DOI]
  42. 박수진, "Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg", kg with JEKHT 100 mg, 대한예방한의학회지, pp.2016, 20(2)[DOI]

관련 논문AI추천

Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with GMODT 100 mg/kg with 2.5 hr-intervals -강수진, 구세광, 류은아, 송창현, 이봉효, 이영준, 최성훈, 한창현대한예방한의학회 · 대한예방한의학회지2017 · 제21권 제2호Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated Co-administration곽민아, 구세광, 박성환, 박수진, 이영준대한예방한의학회 · 대한예방한의학회지2016 · 제20권 제2호Effect of Gongjindan-gamibang on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (2) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan-gamibang 100 mg/kg, 3.5hr-intervals with 7-day Repeated Treatment -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2015 · 제19권 제1호Effect of Gongjindan, a Polyherbal Formula on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (1) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan 100mg/kg within 5min -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2014 · 제18권 제2호Effects of the mixed formulation of sorafenib and blue honeysuckle on the pharmacokinetics profiles of sorafenib강수진, 강현구, 구세광, 이영준, 최성훈대한예방한의학회 · 대한예방한의학회지2019 · 제23권 제1호Effect of Gongjindon a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (1) -Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg within 5 min -구세광, 권오대, 박수진, 이영준, 정대규대한예방한의학회 · 대한예방한의학회지2013 · 제17권 제1호

이 간행물의 다른 논문 (6건)

텍스트마이닝 기법을 이용한 『상한론』 내의 증상-본초 조합의 탐색적 분석김창업, 장동엽, 이충열, 하윤수pp. 159-169八味地黃湯의 ROS 생성 및 p53 활성 조절을 통한 시스플라틴 신장독성 완화효과정명수, 전병훈, 주성민, 박서희pp. 170-176유방암세포에서 LATS1/2 활성에 의한 당귀 추출물의 항암효과신유수, 모정순, 김남빈, 김초롱, 정한솔pp. 177-183시스템 약리학적 분석에 의한 황금의 항균효과김효진, 김윤숙, 박세림, 안원근, 이부균, 하희정pp. 184-190음식물 섭취로 인한 혀 색상 변화가 설진에 미치는 영향유호룡, 박미소, 이주호, 박상수, 김민서, 황윤신, 김기왕pp. 191-200
원문 보기